The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
Year | Volume (Price x Shares) | Change |
---|---|---|
2024 | $10.02 M | -95.63% |
2023 | $0.22 B | -63.52% |
2022 | $0.62 B | 629.28% |
2021 | $86.13 M | -77.97% |
2020 | $0.39 B | 85.64% |
2019 | $0.21 B | -52.97% |
2018 | $0.44 B | 269.88% |
2017 | $0.12 B | -48.45% |
2016 | $0.23 B | -37.53% |
2015 | $0.37 B | -44.13% |
2014 | $0.67 B | 2387.79% |
2013 | $27.05 M |
Company | FTD volume (3months) | FTD volume (1 year) | Country |
---|---|---|---|
Pfizer PFE | $16.08 M | $0.32 B | ๐บ๐ธ USA |
Eli Lilly LLY | $53.06 M | $0.12 B | ๐บ๐ธ USA |
Amgen AMGN | $62.04 M | $0.18 B | ๐บ๐ธ USA |
Biogen BIIB | $23.03 M | $76.93 M | ๐บ๐ธ USA |
Gilead Sciences GILD | $32.63 M | $0.25 B | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $0.23 B | $0.32 B | ๐บ๐ธ USA |
AstraZeneca AZN | $0.10 B | $0.17 B | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $16.24 M | $23.04 M | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $15.51 M | $35.14 M | ๐บ๐ธ USA |